2013 half-year activity
(Unaudited data)
. CUMULATIVE ACTIVITY AS OF THE END OF JUNE 2013
| In thousands of euros | 2012 | 2013 | Variation at current exchange rates | Variation at constant exchange rates |
| France | 145,398 | 159,597 | +9.8% | +9.8% |
| International : | 96,120 | 116,187 | +20.9% | +21.8% |
| Incl. Europe (excluding France) | 70,696 | 83,381 | +17.9% | +18.5% |
| Incl. North America | 20,146 | 25,579 | +27.0% | +28.8% |
| Incl. Other countries | 5,278 | 7,227 | +36.9% | +39.9% |
| Group Total | 241,518 | 275,784 | +14.2% | +14.6% |
| In thousands of euros | 2012 | 2013 | Variation at current exchange rates | Variation at constant exchange rates |
| Non-proprietary Homeopathic Medicines | 143,633 | 152,097 | +5.9% | +6.0% |
| OTC Specialties | 97,583 | 123,466 | +26.5% | +27.3% |
| Other | 302 | 221 | -26.8% | -28.1% |
| Group Total | 241,518 | 275,784 | +14.2% | +14.6% |
. ACTIVITY IN THE QUARTER (variation at current rate)
| In thousands of euros | 1st Quarter | 2nd Quarter | ||||
| 2012 | 2013 | Var. | 2012 | 2013 | Var. | |
| France | 74,188 | 84,270 | +13.6% | 71,210 | 75,327 | +5.8% |
| International : | 54,904 | 73,751 | +34.3% | 41,216 | 42,436 | +3.0% |
| Incl. Europe (excluding France) | 41,807 | 54,334 | +30.0% | 28,889 | 29,047 | +0.5% |
| Incl. North America | 10,285 | 15,562 | +51.3% | 9,861 | 10,017 | +1.6% |
| Incl. Other countries | 2,812 | 3,855 | +37.1% | 2,466 | 3,372 | +36.7% |
| Group Total | 129,092 | 158,021 | +22.4% | 112,426 | 117,763 | +4.7% |
| In thousands of euros | 1st Quarter | 2nd Quarter | ||||
| 2012 | 2013 | Var. | 2012 | 2013 | Var. | |
| Non-proprietary Homeopathic Medicines | 73,427 | 79,062 | +7.7% | 70,206 | 73,035 | +4.0% |
| OTC Specialties | 55,576 | 78,866 | +41.9% | 42,007 | 44,600 | +6.2% |
| Other | 89 | 93 | +4.5% | 213 | 128 | -39.9% |
| Group Total | 129,092 | 158,021 | +22.4% | 112,426 | 117,763 | +4.7% |
2013 SECOND QUARTER HIGHLIGHTS
- After a growth by 22.4% in the first quarter due notably to the strong pathology, sales revenue in the second quarter increased by 4.7% at current exchange rate (+5.2% at constant exchange rate).
- Unda has announced its attention to reorganize its activities in order to ensure the development of homeopathy in Belgium. This project, likely to have social effects on the two Belgian sites, could affect around 60 employees over 194.
- In the United States, the settlement agreement aimed to put an end to the legal proceeding relating to Children's Coldcalm® medicine in California obtained the prior approval of the Los Angeles court. Boiron USA is awaiting the court's final approval of the agreement. A provision of one million US dollars was recorded in the accounts as of December 31, 2011, which we still believe is corresponding to the risk incurred.
- On June 30, 2013, the cash position of the group is exceeding 100 million euros against 94.7 million euros on December 31, 2012.
The half-year profitability should be in noticeable progress. In support of these performances, the group confirms targeting a new increase of its activity and profitability in 2013.
Our next update:
August 29, 2013: at market close, publication of 2013 half-year results.
Person responsible for financial information: Philippe MONTANT
Contact for financial information: Véronique BOUSCAYROL
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : [email protected]
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information is online at: www.boiron.com
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-32800-boi-120713-ca-t2-13-gb.pdf
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Quelle: Actusnews
